Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 67,687 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $29.35, for a total value of $1,986,613.45. Following the transaction, the chief operating officer now owns 706,872 shares in the company, valued at $20,746,693.20. The trade was a 8.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Melissa Baird also recently made the following trade(s):

• On Tuesday, December 10th, Melissa Baird sold 85,561 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.01, for a total value of $2,653,246.61.
• On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded up $1.18 during midday trading on Thursday, reaching $30.90. The company had a trading volume of 9,482,037 shares, compared to its average volume of 10,299,667. The firm has a market cap of $6.75 billion, a PE ratio of 70.22 and a beta of 1.31. The stock has a fifty day moving average price of $27.78 and a 200 day moving average price of $22.03. Hims & Hers Health, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.04) earnings per share. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Raleigh Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. GAMMA Investing LLC grew its holdings in Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after buying an additional 2,152 shares in the last quarter. Quest Partners LLC grew its holdings in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after buying an additional 807 shares in the last quarter. CWM LLC grew its holdings in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Hims & Hers Health by 115.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock worth $110,000 after buying an additional 2,442 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on HIMS shares. Morgan Stanley started coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective on the stock. Piper Sandler lifted their price target on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. BTIG Research assumed coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.